Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

Sandra Söderholm, Maria Anastasina, Mohammad Majharul Islam, Janne Tynell, Minna M. Poranen, Dennis H. Bamford, Jakob Stenman, Ilkka Julkunen, Ingrida Šauliene, Jef K. De Brabander, Sampsa Matikainen, Tuula A. Nyman, Xavier Saelens, Denis Kainov

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

Original languageEnglish (US)
Pages (from-to)69-80
Number of pages12
JournalAntiviral Research
Volume126
DOIs
StatePublished - Feb 1 2016

Fingerprint

gemcitabine
Influenza A virus
Antiviral Agents
Macrophages
Pandemics
Virus Diseases
Coinfection
Innate Immunity
Interferon-alpha
Lipopolysaccharides
Public Health
Pharmaceutical Preparations
saliphenylhalamide
obatoclax
N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide

Keywords

  • Antiviral agents
  • Immune responses
  • Influenza A virus
  • Innate immunity
  • Virus-host interaction

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Söderholm, S., Anastasina, M., Islam, M. M., Tynell, J., Poranen, M. M., Bamford, D. H., ... Kainov, D. (2016). Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. Antiviral Research, 126, 69-80. https://doi.org/10.1016/j.antiviral.2015.12.011

Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. / Söderholm, Sandra; Anastasina, Maria; Islam, Mohammad Majharul; Tynell, Janne; Poranen, Minna M.; Bamford, Dennis H.; Stenman, Jakob; Julkunen, Ilkka; Šauliene, Ingrida; De Brabander, Jef K.; Matikainen, Sampsa; Nyman, Tuula A.; Saelens, Xavier; Kainov, Denis.

In: Antiviral Research, Vol. 126, 01.02.2016, p. 69-80.

Research output: Contribution to journalArticle

Söderholm, S, Anastasina, M, Islam, MM, Tynell, J, Poranen, MM, Bamford, DH, Stenman, J, Julkunen, I, Šauliene, I, De Brabander, JK, Matikainen, S, Nyman, TA, Saelens, X & Kainov, D 2016, 'Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine', Antiviral Research, vol. 126, pp. 69-80. https://doi.org/10.1016/j.antiviral.2015.12.011
Söderholm S, Anastasina M, Islam MM, Tynell J, Poranen MM, Bamford DH et al. Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. Antiviral Research. 2016 Feb 1;126:69-80. https://doi.org/10.1016/j.antiviral.2015.12.011
Söderholm, Sandra ; Anastasina, Maria ; Islam, Mohammad Majharul ; Tynell, Janne ; Poranen, Minna M. ; Bamford, Dennis H. ; Stenman, Jakob ; Julkunen, Ilkka ; Šauliene, Ingrida ; De Brabander, Jef K. ; Matikainen, Sampsa ; Nyman, Tuula A. ; Saelens, Xavier ; Kainov, Denis. / Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. In: Antiviral Research. 2016 ; Vol. 126. pp. 69-80.
@article{480b29aa37384230bf252d82a1a1bb00,
title = "Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine",
abstract = "Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.",
keywords = "Antiviral agents, Immune responses, Influenza A virus, Innate immunity, Virus-host interaction",
author = "Sandra S{\"o}derholm and Maria Anastasina and Islam, {Mohammad Majharul} and Janne Tynell and Poranen, {Minna M.} and Bamford, {Dennis H.} and Jakob Stenman and Ilkka Julkunen and Ingrida Šauliene and {De Brabander}, {Jef K.} and Sampsa Matikainen and Nyman, {Tuula A.} and Xavier Saelens and Denis Kainov",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.antiviral.2015.12.011",
language = "English (US)",
volume = "126",
pages = "69--80",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

AU - Söderholm, Sandra

AU - Anastasina, Maria

AU - Islam, Mohammad Majharul

AU - Tynell, Janne

AU - Poranen, Minna M.

AU - Bamford, Dennis H.

AU - Stenman, Jakob

AU - Julkunen, Ilkka

AU - Šauliene, Ingrida

AU - De Brabander, Jef K.

AU - Matikainen, Sampsa

AU - Nyman, Tuula A.

AU - Saelens, Xavier

AU - Kainov, Denis

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

AB - Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

KW - Antiviral agents

KW - Immune responses

KW - Influenza A virus

KW - Innate immunity

KW - Virus-host interaction

UR - http://www.scopus.com/inward/record.url?scp=84952845480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952845480&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2015.12.011

DO - 10.1016/j.antiviral.2015.12.011

M3 - Article

C2 - 26738783

AN - SCOPUS:84952845480

VL - 126

SP - 69

EP - 80

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -